**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 81112

**Manuscript Type:** CORRECTION

**Correction: Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant**

Brandão ABM *et al*. ICC or HCC-CC after LT

Ajacio Bandeira de Mello Brandão, Santiago Rodriguez, Alfeu de Medeiros Fleck Jr, Claudio Augusto Marroni, Mário B Wagner, Alex Hörbe, Matheus V Fernandes, Carlos TS Cerski, Gabriela Perdomo Coral

**Ajacio Bandeira de Mello Brandão, Santiago Rodriguez, Claudio Augusto Marroni, Matheus V Fernandes, Gabriela Perdomo Coral,** Graduate Program in Medicine: Hepatology, School of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050170, RS, Brazil

**Ajacio Bandeira de Mello Brandão, Alfeu de Medeiros Fleck Jr, Claudio Augusto Marroni,** Liver Transplantation Group, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre 90020090, RS, Brazil

**Santiago Rodriguez,** Department of Hepatology, Hospital Vozandes Quito-HVQ, Quito 170521, Ecuador

**Mário B Wagner,** School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90035002, RS, Brazil

**Alex Hörbe,** Interventional Radiology Unit, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre 90020090, RS, Brunei Darussalam

**Carlos TS Cerski,** Department of Pathology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90035002, RS, Brazil

**Author contributions:** All the authors solely contributed to this paper.

**Corresponding author: Ajacio Bandeira de Mello Brandão, PhD, Researcher,** Graduate Program in Medicine: Hepatology, School of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, R. Eng. Álvaro Nunes Pereira, 400/402, Porto Alegre 90050170, RS, Brazil. ajaciob@gmail.com

**Received:** October 25, 2022

**Revised:** December 6, 2022

**Accepted:** February 1, 2023

**Published online:**

**Abstract**

Rereading the article “Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant” (DOI: 10.5306/wjco.v13.i8.688), published on August 24, we observe, with concern, that figures 3 and 4 are wrong. The authors have attached the correct figures for correction.

**Key Words:** Cholangiocarcinoma; Hepatocellular carcinoma; Liver; Prognosis; Recurrence; Survival analysis; Correction

Brandão ABM, Rodriguez S, Fleck Jr AM, Marroni CA, Wagner MB, Hörbe A, Fernandes MV, Cerski CT, Coral GP. Correction: Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. *World J Clin Oncol* 2022; In press

**Core Tip:** The authors have attached the correct figures for correction rereading the article “Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant” (DOI: 10.5306/wjco.v13.i8.688).

**TO THE EDITOR**

Rereading our article “Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant”[1] (DOI: 10.5306/wjco.v13.i8.688), published on August 24, we observe, with concern, that figures 3 and 4 are wrong. At some point, we have mistakenly forwarded a wrong file. Therefore, we attach the correct figures for correction (Figures 1 and 2). We hope that it will be possible to replace the wrong figures with the correct ones and that this process will not be difficult. We apologize in advance for this unfortunate mistake. Of note, correction does not change the interpretation of results or conclusion.

**REFERENCES**

1 **Brandão ABM**, Rodriguez S, Fleck AM Jr, Marroni CA, Wagner MB, Hörbe A, Fernandes MV, Cerski CT, Coral GP. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. *World J Clin Oncol* 2022; **13**: 688-701 [PMID: 36160465 DOI: 10.5306/wjco.v13.i8.688]

**Footnotes**

**Conflict-of-interest statement:** All authors have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 25, 2022

**First decision:** November 25, 2022

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Rizzo A, Italy; Wei W, China; Zharikov YO, Russia **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL

**Figure Legends**

****

**Figure 1 Corrected “Figure 3”.** A-D:Kaplan-Meier curves representing post-liver transplant overall survival and recurrence-free survival in patients with intrahepatic cholangiocarcinoma (ICC) compared with patients with hepatocellular carcinoma (HCC), matched 1:8 for pretransplant tumor characteristics (A and B) and posttransplant tumor characteristics (C and D). HRs: Hazard ratios; CI: Confidence interval.

****

**Figure 2 Corrected “Figure 4”.** A-D: Kaplan-Meier curves representing post-liver transplant overall survival and recurrence-free survival in patients with mixed hepatocellular-cholangiocarcinoma (HCC-CC) compared with patients with HCC, matched 1:8 for pretransplant tumor characteristics (A and B) and posttransplant tumor characteristics (C and D). HRs: Hazard ratios; CI: Confidence interval.